# US 2002/0165120 A1 · Compositions having improved bioavailability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0165120 A1
- Document ID: US20020165120A1
- Status: Published application
- Kind: A1
- Application number: 10/075,800
- Filed: 2002-02-13
- Published: 2002-11-07
- Earliest claimed: 2001-03-01
- Assignees: Pfizer Inc.
- Inventors: Michael John Humphrey
- Web page: https://patentgrep.com/patent/US20020165120A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 25/06: Antimigraine agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition comprising eletriptan and a p-glycoprotein (p-gp) inhibitor useful for the treatment of migraine. The bioavailability of eletriptan can be increased by co-administering eletriptan with a p-gp inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit. Also provided is a method of treating migraine using said composition or sequential administration of components.

## Claims

### Claim 1

A method of treating migraine in a subject comprising administering to said subject an amount of a composition comprising eletriptan in combination with a p-gp inhibitor effective to treat migraine in said subject, or administering in sequence to said subject eletriptan and a p-gp inhibitor, each in an amount effective to treat migraine in said subject.

### Claim 2 (depends on 1)

The method of treating migraine according to claim 1 wherein said p-gp inhibitor is not otherwise pharmaceutically active.

### Claim 3 (depends on 1)

The method of treating migraine according to claim 1 wherein said p-gp inhibitor is pharmaceutically active other than as a p-gp inhibitor.

### Claim 4 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by AUC, of at least 25% relative to dosing in absence of p-gp inhibitor.

### Claim 5 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by AUC, of at least 50% relative to dosing in absence of p-gp inhibitor.

### Claim 6 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by AUC, of 100% relative to dosing in absence of p-gp inhibitor.

### Claim 7 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by Cmax, of at least 50% relative to dosing in absence of p-gp inhibitor.

### Claim 8 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by Cmax, of at least 100% relative to dosing in absence of p-gp inhibitor.

### Claim 9 (depends on 1)

The method of treating migraine according to claim 1 wherein said composition provides an increase in oral bioavailability of eletriptan, as measured by Cmax, of at least 200% relative to dosing in absence of p-gp inhibitor.

### Claim 10 (depends on 5)

The method of treating migraine according to claim 5 wherein said increase is measured in blood serum.

### Claim 11 (depends on 5)

The method of treating migraine according to claim 5 wherein said composition provides an oral bioavailability for eletriptan, as measured by AUC, of greater than 50%.

### Claim 12 (depends on 5)

The method of treating migraine according to claim 5 wherein said composition improves rate of onset of migraine abortion by at least 25% relative to dosing in absence of p-gp inhibitor.

### Claim 13

A pharmaceutical composition comprising eletriptan, a p-gp inhibitor and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 14 (depends on 13)

The composition according to claim 13 wherein said p-gp inhibitor is not otherwise pharmaceutically active.

### Claim 15 (depends on 13)

The composition according to claim 13 wherein said p-gp inhibitor is also pharmaceutically active.

### Claim 16 (depends on 13)

The composition according to claim 13 wherein oral bioavailability of eletriptan, as measured by AUC, is increased by at least 25% relative to dosing in absence of p-gp inhibitor.

### Claim 17 (depends on 13)

The composition according to claim 13 wherein oral bioavailablility of eletriptan, as measured by AUC, is increased by at least 50% relative to dosing in absence of p-gp inhibitor.

### Claim 18 (depends on 13)

The composition according to claim 13 wherein oral bioavailability of eletriptan, as measured by AUC, is increased by 100% relative to dosing in absence of p-gp inhibitor.

### Claim 19 (depends on 13)

The composition according to claim 13 wherein oral bioavailability of eletriptan, as measured by Cmax, is increased by an least 50% relative to dosing in absence of p-gp inhibitor.

### Claim 20 (depends on 13)

The composition according to claim 13 wherein oral bioavailablility of eletriptan, as measured by Cmax, is increased by at least 100% relative to dosing in absence of p-gp inhibitor.

### Claim 21 (depends on 13)

The composition according to claim 13 wherein oral bioavailability of eletriptan, as measured by Cmax, is increased by at least 200% relative to dosing in absence of p-gp inhibitor.

### Claim 22 (depends on 16)

The composition according to claim 16 wherein said increase is measured in blood serum.

### Claim 23 (depends on 13)

The composition according to claim 13 which improves rate of onset of migraine abortion by at least 25% relative to dosing in absence of p-gp inhibitor.

### Claim 24

A kit comprising
(1) a therapeutically effective amount of a composition comprising eletriptan and a pharmaceutically acceptable carrier, diluent, or excipient, in a first dosage form;
(2) a therapeutically effective amount of a composition comprising a compound which is a p-gp inhibitor and a pharmaceutically acceptable carrier, diluent, or excipient, in a second dosage form; and
(3) a container for containing said first and second dosage forms.
